Alternative statistical strategies for biosimilar drug development
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 1
Abstract
Introduction: Many regulatory authorities have published requirements for the approval of biosimilar medicinal products. However, there is no guidance on which quantitative standards should be used to define how similar a follow-on product must be to be considered biosimilar. Sample sizes for clinical biosimilar trials using traditional designs often exceed 500 patients. Several publications have referenced alternative methods to calculate biosimilar trial sample sizes. Few, however, provide actual case studies showing the order of magnitude change possible. We modelled alternate statistical approaches to practical case studies to test whether it is possible to reduce the sample size of clinical biosimilar trials. Methods: Clinical case studies of bevacizumab, adalimumab and rituximab biosimilars were used as models. A traditional frequentist model was compared to a repeated measures analysis, a batch-to-batch method, and a Bayesian method. Statistical modelling and sample size calculations were performed using PASS version 12 and SAS version 9.2. Repeated measures analysis was performed using a generalized estimating equation method. Sample size and power were estimated by simulations. Sample size estimation for the Bayesian method was based on beta-binomial distribution of the posterior distribution of response rate. Results: In all cases, the repeated measures analysis and Bayesian design resulted in reduced sample sizes compared to a traditional approach (3–11% and 26–29% reduction, respectively). The batch-to-batch method resulted in larger sample size estimates compared to the traditional approach. Conclusion: The utilization of non-traditional statistical approaches is strongly encouraged when developing a biosimilar due to the potential to reduce the sample sizes needed. Discussion with regulatory authorities is required before using these methods during the clinical development of any biosimilar.
Authors and Affiliations
Austin J Combest, Song Wang, Brian T Healey, Dirk J Reitsma
Keywords
Related Articles
- EP ID EP354161
- DOI 10.5639/gabij.2014.0301.006
- Views 149
- Downloads 0
‘Similar biologics’ approved and marketed in India
There have been established guidelines for approving generic versions of small molecule chemical drugs in India for some time already. However, no specific guidelines for ‘similar biologics’, as the Indian regulatory aut...
What to look forward to in GaBI Journal, 2012, issue 2
It is my pleasure to introduce the second edition of GaBI Journalwhich contains a number of interesting articles. Professors Benjamin and Kearns present a review of advances in paediatric drug development and labelling,...
GaBI Journal publishes four issues in 2013
This issue marks the forth and final issue of the second year’s edition of the GaBI Journal. The journal has grown rapidly through the combined efforts of the publisher and her staff, all of the members of the executive...
A review of generic medicine pricing in Europe
Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is to review generic medi...
Reference pricing systems in Europe: characteristics and consequences
Introduction: A reference pricing system is a system that establishes a common reimbursement level or reference price for a group of interchangeable medicines, i.e. the reference group. This article provides an overview...